COVID-19 Associated Coagulopathy and Thrombotic Complications
The SARS-CoV-2 virus caused a global pandemic within weeks, causing hundreds of thousands of people infected. Many patients with severe COVID-19 present with coagulation abnormalities, including increase D-dimers and fibrinogen. This coagulopathy is associated with an increased risk of death. Furthe...
Main Authors: | , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2020-08-01
|
Series: | Clinical and Applied Thrombosis/Hemostasis |
Online Access: | https://doi.org/10.1177/1076029620948137 |
id |
doaj-2c807172a1164be2a6e2422a192d0cbe |
---|---|
record_format |
Article |
spelling |
doaj-2c807172a1164be2a6e2422a192d0cbe2020-11-25T04:08:22ZengSAGE PublishingClinical and Applied Thrombosis/Hemostasis1938-27232020-08-012610.1177/1076029620948137COVID-19 Associated Coagulopathy and Thrombotic ComplicationsZoubida Tazi Mezalek0Hajar Khibri1Wafaa Ammouri2Majdouline Bouaouad3Soukaina Haidour4Hicham Harmouche5Mouna Maamar6Mohamed Adnaoui7 Faculty of Medicine and Pharmacy, Mohammed V University, Rabat, Morocco Faculty of Medicine and Pharmacy, Mohammed V University, Rabat, Morocco Faculty of Medicine and Pharmacy, Mohammed V University, Rabat, Morocco Clinical Hematology Department, Ibn Sina University Hospital, Rabat, Morocco Clinical Hematology Department, Ibn Sina University Hospital, Rabat, Morocco Faculty of Medicine and Pharmacy, Mohammed V University, Rabat, Morocco Faculty of Medicine and Pharmacy, Mohammed V University, Rabat, Morocco Faculty of Medicine and Pharmacy, Mohammed V University, Rabat, MoroccoThe SARS-CoV-2 virus caused a global pandemic within weeks, causing hundreds of thousands of people infected. Many patients with severe COVID-19 present with coagulation abnormalities, including increase D-dimers and fibrinogen. This coagulopathy is associated with an increased risk of death. Furthermore, a substantial proportion of patients with severe COVID-19 develop sometimes unrecognized, venous, and arterial thromboembolic complications. A better understanding of COVID-19 pathophysiology, in particular hemostatic disorders, will help to choose appropriate treatment strategies. A rigorous thrombotic risk assessment and the implementation of a suitable anticoagulation strategy are required. We review here the characteristics of COVID-19 coagulation laboratory findings in affected patients, the incidence of thromboembolic events and their specificities, and potential therapeutic interventions.https://doi.org/10.1177/1076029620948137 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Zoubida Tazi Mezalek Hajar Khibri Wafaa Ammouri Majdouline Bouaouad Soukaina Haidour Hicham Harmouche Mouna Maamar Mohamed Adnaoui |
spellingShingle |
Zoubida Tazi Mezalek Hajar Khibri Wafaa Ammouri Majdouline Bouaouad Soukaina Haidour Hicham Harmouche Mouna Maamar Mohamed Adnaoui COVID-19 Associated Coagulopathy and Thrombotic Complications Clinical and Applied Thrombosis/Hemostasis |
author_facet |
Zoubida Tazi Mezalek Hajar Khibri Wafaa Ammouri Majdouline Bouaouad Soukaina Haidour Hicham Harmouche Mouna Maamar Mohamed Adnaoui |
author_sort |
Zoubida Tazi Mezalek |
title |
COVID-19 Associated Coagulopathy and Thrombotic Complications |
title_short |
COVID-19 Associated Coagulopathy and Thrombotic Complications |
title_full |
COVID-19 Associated Coagulopathy and Thrombotic Complications |
title_fullStr |
COVID-19 Associated Coagulopathy and Thrombotic Complications |
title_full_unstemmed |
COVID-19 Associated Coagulopathy and Thrombotic Complications |
title_sort |
covid-19 associated coagulopathy and thrombotic complications |
publisher |
SAGE Publishing |
series |
Clinical and Applied Thrombosis/Hemostasis |
issn |
1938-2723 |
publishDate |
2020-08-01 |
description |
The SARS-CoV-2 virus caused a global pandemic within weeks, causing hundreds of thousands of people infected. Many patients with severe COVID-19 present with coagulation abnormalities, including increase D-dimers and fibrinogen. This coagulopathy is associated with an increased risk of death. Furthermore, a substantial proportion of patients with severe COVID-19 develop sometimes unrecognized, venous, and arterial thromboembolic complications. A better understanding of COVID-19 pathophysiology, in particular hemostatic disorders, will help to choose appropriate treatment strategies. A rigorous thrombotic risk assessment and the implementation of a suitable anticoagulation strategy are required. We review here the characteristics of COVID-19 coagulation laboratory findings in affected patients, the incidence of thromboembolic events and their specificities, and potential therapeutic interventions. |
url |
https://doi.org/10.1177/1076029620948137 |
work_keys_str_mv |
AT zoubidatazimezalek covid19associatedcoagulopathyandthromboticcomplications AT hajarkhibri covid19associatedcoagulopathyandthromboticcomplications AT wafaaammouri covid19associatedcoagulopathyandthromboticcomplications AT majdoulinebouaouad covid19associatedcoagulopathyandthromboticcomplications AT soukainahaidour covid19associatedcoagulopathyandthromboticcomplications AT hichamharmouche covid19associatedcoagulopathyandthromboticcomplications AT mounamaamar covid19associatedcoagulopathyandthromboticcomplications AT mohamedadnaoui covid19associatedcoagulopathyandthromboticcomplications |
_version_ |
1724426117429854208 |